America spent approximately $5.3 trillion on health care in 2024—more than $15,000 per person. Yet enormous sums still purchase avoidable injuries, repetitive paperwork, unnecessary procedures, preventable addiction, litigation overhead and painful treatment that offers dying patients no meaningful benefit. (CMS)
A reasonable accounting of the reforms proposed here identifies approximately:
$100 billion to $140 billion a year in potentially avoidable expenditures and property losses
$140 billion to $150 billion in recovered productivity and professional capacity
A core tangible economic opportunity of roughly $245 billion to $290 billion a year
Additional liability and payment-integrity reforms that could bring the practical target to approximately $300 billion annually
$1.5 trillion to $2.5 trillion in broader annual social value when the economic value of lives and healthy years preserved is included
The distinction is essential. A life saved has immense economic value, but it does not deposit that value into the Treasury. Likewise, freeing a physician from unnecessary typing creates productive capacity, but it becomes cash savings only if the capacity is actually redeployed.
The estimates below therefore separate expenditures avoided, productivity recovered and the broader economic value of better health.
| Reform | Plausible annual tangible benefit | What the estimate represents |
|---|---|---|
| Reduce drug-related harm toward Singapore’s rate | About $198 billion | Approximately $65B in health, treatment and justice costs; $134B in productivity |
| Near-zero preventable medical error | $26B–$45B | Avoidable treatment and hospital costs |
| Automatic emergency braking and vehicle intervention | More than $5B | Primarily property damage, before valuing lives and injuries |
| Bedside urinals and nighttime fall prevention | $5B–$15B | Scenario based on preventing 5%–15% of older-adult fall costs |
| Early palliative care and limits on nonbeneficial treatment | $3B–$7B | Gross hospital savings under a scaled implementation scenario |
| AI-generated encounter documentation | $8B–$17B | Recovered clinical capacity, not necessarily reduced spending |
| Liability and defensive-medicine reform | $18B–$35B | Partial realization of an older addressable-cost estimate |
| Payment-integrity enforcement | $19B–$38B | Scenario capturing 20%–40% of identified improper-payment exposure |
| Patent, approval, outcome-payment and genetic reforms | Not counted | Too dependent on policy design and future technologies |
These figures should not simply be added together. Defensive medicine, payment errors, preventable harm and low-value treatment overlap. The defensible conclusion is not that every theoretical dollar can be collected. It is that a $300 billion annual prevention dividend is a credible national objective.
Make medical error as exceptional as an airline catastrophe
The most important reform is to treat every serious preventable medical injury as aviation treats a crash: investigate it independently, identify every contributing system failure, publish de-identified findings and require corrective action.
Federal investigators found that approximately one-quarter of hospitalized Medicare patients experienced some form of harm in one studied month. About 13% experienced harm judged preventable. (HHS Office of Inspector General)
Older studies estimated the direct annual cost of measurable preventable hospital errors at approximately $17 billion to $29 billion. Adjusted roughly into 2026 dollars, that is about $26 billion to $45 billion. (Commonwealth Fund, AHRQ Patient Safety Network)
That estimate excludes much of the lost work, disability, family caregiving and economic value of premature deaths. A modern meta-analysis estimated approximately 22,000 preventable inpatient deaths annually, while earlier national estimates ranged as high as 75,000 to 98,000. (PubMed, AHRQ Patient Safety Network)
Using a standard regulatory value of a statistical life, those deaths represent roughly $300 billion to more than $1 trillion in annual social loss. That is not a medical bill and should never be represented as budget revenue. It is the economic measure government agencies use when deciding whether safety regulations are worth their cost.
The reform should include protected reporting. Findings disclosed completely to an independent safety authority—and published in de-identified form—should generally be protected from use as admissions in civil litigation. Concealment, alteration of records and failure to report would remain punishable. The purpose is to make truthful investigation safer than silence.
Replace the malpractice lottery with dependable patient compensation
The present malpractice system is costly, slow and unreliable. One major study found that approximately 54 cents in administrative expense was generated for every dollar paid as compensation, including legal fees, experts and court costs. (New England Journal of Medicine study)
A better system would provide:
Prompt administrative compensation for qualifying medical injuries
Published compensation schedules with additions for exceptional losses
Independent medical adjudication
Payment of reasonable representation costs separately from patient compensation
Preservation of court remedies for intentional wrongdoing, concealment and extreme misconduct
This would distribute compensation more consistently among injured patients instead of concentrating large awards among the comparatively small number who find representation and prevail after years of litigation.
It could also reduce defensive medicine. A national analysis estimated medical-liability-system costs at $55.6 billion in 2008, including $45.6 billion attributed to defensive medicine. In approximate 2026 dollars, the latter would exceed $70 billion. (Health Affairs)
It would be unrealistic to assume that every dollar disappears. If reform eliminated only one-quarter to one-half of the old inflation-adjusted defensive-medicine estimate, the potential benefit would be approximately $18 billion to $35 billion annually. Because some of this spending overlaps other categories, it should be treated as supporting evidence for the $300 billion target rather than automatically added to it.
Stop paying for time, typing and unnecessary activity
Health care often pays for measurable activity instead of useful results. A clinician who recognizes a dangerous condition in two minutes may create more value than one who conducts a routine 20-minute encounter. Payment should recognize diagnostic skill, complexity, appropriate follow-up and outcomes—not merely elapsed time.
At the same time, clinicians should not spend large portions of their days typing information that can be generated from the encounter itself. With patient notice and appropriate privacy protections, encounters can be recorded, transcribed and converted into draft notes, orders and patient instructions. The clinician must remain responsible for reviewing and signing the record.
Controlled studies of ambient AI documentation have found reductions in time spent writing notes and improvements in burnout measures, although safety review remains necessary. (JAMA Network Open, randomized trial)
If one million clinicians recovered only 15 to 30 minutes per working day, the country would regain roughly 55 million to 110 million professional hours annually. At an illustrative value of $150 per clinical hour, that is $8 billion to $17 billion in productive capacity.
This is not automatically a reduction in national health spending. The gain appears when the recovered time is used to see more patients, reduce staffing requirements, shorten waiting lists or improve safety.
Treat knowingly unnecessary billing as a compliance offense
A medically appropriate decision not to perform a test must be safe legally. Conversely, knowingly billing for services that are not medically necessary should be treated as a serious payment-integrity violation.
A fair enforcement system should distinguish mistakes from repeated misconduct:
Correct the first substantiated violation and provide education.
Issue a formal warning and repayment demand for the second.
Apply prosecution or substantial administrative penalties to the third knowing violation and subsequent violations.
Fraud, falsified records and intentional patient harm should not receive warnings.
In fiscal year 2025, CMS reported approximately $94 billion in gross improper payments across Medicare fee-for-service, Medicare Advantage, Part D and Medicaid. Improper payments are not synonymous with fraud; many involve insufficient documentation or other payment errors. (CMS)
Preventing or recovering 20% to 40% of that exposure would represent approximately $19 billion to $38 billion annually. Some of it overlaps unnecessary-care and defensive-medicine estimates, so it should not be counted twice.
Capture the enormous economic benefit of preventing addiction
Drug-use disorders cause medical spending, treatment costs, policing, incarceration, disability, absenteeism, impaired work, accidents and premature death.
A comparison using Global Burden of Disease rates indicates that if the United States matched Singapore’s age-standardized drug-use-disorder mortality rate, annual deaths could fall by roughly 70,000, while more than six million disability-adjusted healthy years could be preserved. (Journal of Global Health)
Applying those proportional reductions to a detailed US estimate of the opioid-use-disorder and fatal-overdose burden produces an illustrative annual benefit, in approximate 2026 dollars, of:
$65 billion in avoided health, treatment and criminal-justice costs
$134 billion in recovered productivity
Approximately $1.16 trillion in the economic value of preserved life and health
The underlying US cost study estimated a 2017 opioid burden exceeding $1 trillion, most of which was the value of premature death and reduced quality of life. (CDC, peer-reviewed cost analysis)
This is a counterfactual, not proof that punishment alone produces Singapore’s outcomes. Singapore differs from the United States in geography, enforcement certainty, social conditions, health services and drug-market access. A successful American policy would need prevention, rapid treatment, recovery support and consistent enforcement—not severity without effectiveness.
Nevertheless, the scale is unmistakable: addiction prevention is potentially the largest individual component of the tangible prevention dividend.
Prevent nighttime falls with simple equipment
Falls among older Americans generate approximately three million emergency-department visits and one million hospitalizations annually. A CDC-supported analysis estimated $80 billion in nonfatal fall-related medical expenditures in 2020, equivalent to roughly $103 billion in 2026 dollars. (CDC, cost study)
Toileting is a significant contributor to inpatient falls, particularly when older patients attempt to walk without assistance at night. (PubMed)
Bedside male and female urinals, safe disposable liners, lighting, handrails, medication review and scheduled assistance should therefore be routine options—not objects of embarrassment. If such measures prevented only 5% to 15% of national older-adult fall costs, gross medical savings could approach $5 billion to $15 billion annually.
That range is a policy scenario, not the measured effect of urinals alone. It should be tested in hospitals, nursing facilities and home-health programs before national savings are booked.
Let vehicles intervene before a collision
Automatic emergency braking and related driver-assistance systems can detect rapidly rising crash risk and intervene before a human reacts.
The National Highway Traffic Safety Administration estimates that its automatic-emergency-braking requirement will save at least 360 lives, prevent approximately 24,000 injuries and avoid more than $5 billion in property damage each year. (NHTSA)
The $5 billion is a tangible annual saving. The value of the lives preserved adds approximately another $5 billion in social benefit, before counting prevented injuries, medical treatment, emergency response, traffic disruption and lost work.
Replace futile treatment with honest end-of-life care
Care near death is not automatically wasteful. Many treatments relieve suffering or provide valuable time. But invasive treatment that has no reasonable prospect of achieving a patient’s goals can inflict pain while consuming hundreds of thousands of dollars.
Early palliative-care consultation has been associated with lower direct hospital costs. A meta-analysis found an average reduction of approximately $3,237 per admission in 2015 dollars when palliative care began within three days. (JAMA Internal Medicine) A Medicare demonstration also reported lower net spending and fewer hospital admissions among participating beneficiaries. (CMS)
If early consultation and enforceable advance-care planning reached one million suitable high-risk admissions, gross savings could be approximately $4 billion to $5 billion annually. A broader implementation might produce $3 billion to $7 billion, depending on eligibility and program cost.
This policy must never become forced undertreatment. The governing standard should be informed patient preference, realistic prognosis, symptom relief and independent review—not age, disability or a family’s wealth. Some palliative-care programs improve care without lowering spending, so savings should remain a secondary objective rather than the bedside decision rule.
Shorten monopoly periods without weakening safety review
A five-year effective post-approval exclusivity period would bring generic or biosimilar competition forward for many products. A presumptive six-month review deadline could also force agencies to identify specific deficiencies promptly rather than allowing applications to remain unresolved.
But these two reforms have different budget effects.
Earlier generic competition could produce large savings. As a simple illustration, if a medicine has $10 billion in annual sales and competition reduces its net price by 80%, beginning competition five years earlier could generate as much as $40 billion in gross savings over those five years.
Faster approval, however, does not necessarily reduce spending. It may bring an expensive but valuable treatment to patients sooner. The gain may appear in longer life, avoided disability or future medical savings rather than an immediate reduction in the drug budget.
Any redesign must also preserve sufficient incentives for expensive, high-risk research. A better policy would tie exclusivity to the date of actual approval, require transparent development-cost evidence for extensions and reward therapies according to demonstrated clinical value.
Invest in cures—but do not pretend the savings have already arrived
Public investment in gene engineering for familial hypercholesterolemia, inherited cardiomyopathies, sickle-cell disease and other familial chronic conditions could eventually replace decades of medication, hospitalization and disability with a one-time intervention.
That is potentially transformational. It is not an immediate budget cut.
Research programs require substantial upfront public spending, and early gene therapies can be extraordinarily expensive. For that reason, no speculative genetic-engineering savings are included in the $300 billion target. The investment should be judged by long-term cost per healthy year gained, durability of benefit and whether public financing produces affordable public access.
The honest bottom line
A prudent annual accounting is:
Avoidable medical, treatment, justice and property expenditures: approximately $100 billion to $140 billion
Recovered worker and clinician productivity: approximately $140 billion to $150 billion
Core tangible economic benefit: approximately $245 billion to $290 billion
Practical national target after carefully designed liability and payment reforms: approximately $300 billion a year
Ten-year tangible opportunity, before growth and discounting: roughly $2.5 trillion to $3 trillion
Broader annual social value, including lives and healthy years preserved: approximately $1.5 trillion to $2.5 trillion
These are gross opportunities. Implementation costs—treatment capacity, safety investigators, compensation administrators, equipment, software, enforcement, palliative teams and research—must be deducted. Results must also be measured so that overlapping savings are never counted twice.
A major review previously estimated total US health-system waste at $760 billion to $935 billion annually, with interventions then available potentially saving $191 billion to $286 billion. (JAMA) That provides a useful reality check: a $300 billion prevention dividend is ambitious, but it is not fantastical in a $5.3 trillion system.
The central economic principle is simple. The cheapest medical catastrophe is the one that never happens. The least expensive overdose is the addiction prevented. The least expensive fall is the safe bedside transfer. The least expensive malpractice case is the error learned from before it is repeated. And the most valuable hour in medicine is the one a skilled clinician spends helping a patient rather than serving a billing system.
No comments:
Post a Comment